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Use of Biosurgicals in 
Hepatobiliary Surgery
Jesse Clanton and Kimberly Seal
Abstract
Through innovative technologies and refinement of surgical technique over the 
last several decades, hepatopancreatobiliary (HPB) surgeries have become increas-
ingly common for both malignant and benign disease. HBP surgeries often present 
unique challenges even for the experienced surgeon, whether due to liver cirrhosis 
causing portal hypertension and impairment of natural clotting abilities or a large 
pancreatic mass invading into nearby mesenteric vessels. Major intraoperative 
blood loss is still a concern and is known to be a major factor influencing morbid-
ity and mortality. Biosurgicals are increasingly used as adjuncts to reduce blood 
loss during these complex procedures, but also to even reduce rates of biliary and 
pancreatic leaks and fistulas postoperatively. While initially biosurgical agents 
offered some hope to make the difference in completing a safe and effective opera-
tion, more recent and rigorous studies have failed to demonstrate reproducible 
benefits. This chapter reviews the use of hemostatic agents in the setting of hepato-
biliary and pancreatic surgery, including for the maintenance of hemostasis and the 
prevention of biliary and pancreatic leaks. We also discuss what factors should be 
considered when choosing the correct agents for different clinical scenarios during 
HPB surgery.
Keywords: hemostasis, hemostatic agent, biosurgical, hepatic surgery, 
pancreatic surgery, hepatobiliary surgery
1. Introduction
Hepatobiliary surgery has increased in frequency throughout the United States 
and the rest of the world over the past several decades. What was once only per-
formed in select specialized centers is now routinely accomplished with equivalent 
outcomes in regional hospitals throughout the world. Even transplantations, exten-
sive en bloc pancreatic surgeries, and major hepatic resections involving multiple 
liver segments are now performed regularly at high volume centers with little blood 
loss. This is in part due to increased incidence of pancreatic and hepatic malignan-
cies requiring resection along with innovations and improvements of surgical 
technique such that patients once considered inoperable are now able to success-
fully undergo extensive surgery. Pancreatic cancer especially has seen increasing 
incidence over time, with nearly 50,000 new cases of pancreatic cancer diagnosed 
in 2016, compared to less than 30,000 in 1999 [1]. Additionally, as other types of 
cancer patients such as colorectal and breast enjoy increased overall survival with 
improved adjuvant therapies, the likelihood that these patients will live long enough 
to eventually develop recurrent or metastatic disease increases as well. Greater than 
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50% of all colorectal cancer patients will eventually develop hepatic metastases 
[2]. Given that colorectal cancer alone accounts for nearly 150,000 new cancer 
cases yearly in the United States [1], this quickly adds up to a significant number 
of patients that have the potential to receive and benefit from hepatic resection or 
transplantation.
Fortunately, both morbidity and mortality have significantly decreased over 
the years as the number of hepatobiliary and pancreatic surgeries have increased. 
A number of reasons can explain the observed improved outcomes, from bet-
ter patient selection, to pre- and perioperative optimization, to modification 
and refinement of surgical technique. Certainly one important factor relating 
to surgical technique has been the ability to perform these major and often 
prolonged surgeries with minimal blood loss and frequently without the need 
for blood transfusion. Hepatobiliary and pancreatic surgeries especially are at 
risk for major blood loss. This is due to multiple factors including substantial 
vascularity of the organs involved, close proximity to important major vascular 
structures that typically must be preserved, and concomitant pathologies such 
as cirrhosis and/or portal hypertension that predispose the patient to increased 
blood loss. Minimizing blood loss remains important as blood loss and blood 
transfusions have been shown to be associated with increased morbidity and 
mortality in these procedures [3–6]. However, only fairly recently have most HPB 
surgeries been routinely performed without significant blood loss and transfusion 
requirements [7].
Whole industries have dedicated themselves to helping the surgeon minimize 
blood loss during an operation, and the modern operating theater is typically filled 
with not only the clamps and sutures of old, but also energy devices, staplers, and 
an increasing array of topical agents used to assist in hemostasis. Biosurgicals have 
now become an increasingly available tool to the surgeon in creating and maintain-
ing hemostasis. There are a multitude of different agents available, from physical 
agents that primarily provide a scaffolding for the platelet plug to form, to biologi-
cally active agents which have added thrombin, fibrin, or other components of the 
coagulation cascade to aid in clotting, to a combination of both. As the technology 
and availability rapidly grows, it can be challenging for the surgeon to decide which 
particular agents can or should be used in a given situation. Every surgeon should 
be aware of the unique aspects of HPB surgery in order to properly evaluate how 
Location Situation Challenge Suggested biosurgical use
Liver Irregular surface area 
after injury or resection
Difficulty to visualize bleeding 
or applying manual pressure
Liquid agents such as fibrin or 
thrombin
Liver Extensive fatty liver 
disease
Difficulty for parenchyma to 
hold sutures
Physical agents such as 
collagen fleece to aid 
hemostasis and tamponade
Liver Cirrhosis or fibrosis Increased bleeding due to 
decreased natural clotting 
ability
Bioactive hemostatic agents to 
deliver thrombin and/or fibrin 
to the tissue
Pancreas Pancreatitis Obscured tissue planes, friable 
tissues
Physical agents or combination 
agents to apply pressure
Pancreas Vessel reconstruction High risk of bleeding, tendency 
to bleed at suture line
Fibrin glues to aid hemostasis 
at vascular anastomosis site
Table 1. 
Biosurgical agents for specific situations IN HPB surgery.
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biosurgicals may be able to aid in reduction and prevention of blood loss and other 
complications. Specific circumstances encountered during hepatic and pancreatic 
surgery may require different solutions that can be aided by biosurgicals (Table 1).
We would like to be clear that use of biosurgicals, especially in hepatobiliary 
surgery, is no substitute for good perioperative management and surgical technique. 
The greatest ability to maintain adequate hemostasis will always be from perfor-
mance of proper basic surgical principles in a thorough and methodical fashion. 
However even despite significant experience, rigorous technique, and best efforts, 
hepatobiliary and general surgeons may find themselves in situations where bleed-
ing is difficult to visualize, access, control, or a combination of all three. In these 
scenarios biosurgicals represent another tool for the surgeon to utilize in order to 
perform safe and effective surgery.
2. Hepatic surgery
Although it appears easily accessible and readily visible during any standard 
laparotomy, the liver can still be a challenging organ to operate on. The liver has 
a dual blood supply, receiving inflow from both the hepatic artery as well as the 
portal vein. Together these vessels channel vast amounts of blood through the liver. 
The liver receives 25% of the total cardiac output, despite only being typically 2.5% 
of the body weight. In a normal adult, this means that the total liver blood flow will 
range from 800 to 1200 ml/min [8]! Even small areas of injured parenchyma may 
lose a significant amount of blood if not identified and controlled due to the large 
volumes of blood flowing through the liver. During a major liver resection, large 
surface areas of the parenchyma may be cut and exposed at one time, which only 
increases the opportunity for blood loss.
The voluminous and rapid flow of blood through the liver is not the only reason 
for a significant opportunity for blood loss during hepatic surgery, however. The 
hepatic parenchyma, the primary substance of the liver made up of hepatocytes, 
can be quite challenging to work with and achieve hemostasis. Any hepatobiliary 
surgeon can tell you the challenges – or even futility – of trying to clip or suture 
directly to liver parenchyma. Suture material will often slide through this soft 
tissue, often doing more damage and causing more bleeding. Whenever feasible 
sutures should incorporate the Glissonean capsule of the liver which generally 
has much more strength to hold a suture in place, but this is not always possible. 
Additionally, liver injury or transection may leave behind an irregular and uneven 
parenchymal surface, limiting the ability to access the bleeding point or to even 
apply manual pressure in an effective manner. Adding to the difficulty is the fact 
that the majority of the vascular and biliary anatomy lies hidden within the hepatic 
parenchyma, and is not readily visible without ultrasound or fluoroscopic guidance. 
Therefore, the surgeon should take care when placing a suture or even stapler into 
the liver to stop bleeding lest an even larger vessel or bile duct that resides nearby 
sustain injury.
An additional complicating factor in hepatic surgery involves the variability of 
hepatic anatomy. Nowhere else in the human body is there such variability for such 
major vascular and anatomic structures. Even a strong background and knowledge 
of common anatomical relationships will not always adequately prepare the sur-
geon. Nearly half of all patients will present with some form of vascular anomaly 
of the hepatic artery alone [9]. When also considering the bile ducts, portal veins, 
and hepatic veins, it can sometimes feel like every patient encountered has some 
form of anomaly. This becomes even more complex when considering that much 
Biosurgicals - The Next Frontier in Operative Approaches
4
of the vasculature of the liver is not readily visible but is concealed within the liver 
parenchyma as noted above.
All of the considerations that have been raised thus far generally concern a 
patient with a normal healthy liver. Unfortunately, a large portion of patients who 
need hepatic surgery have significantly diseased livers. While traditionally this has 
meant cirrhosis and fibrosis with the possibility of portal hypertension, fatty liver 
disease and liver steatosis are also becoming increasing common. The intrinsic 
function of the liver is intimately tied to hemostasis, as the liver is responsible for 
synthesizing and circulating most of the body’s coagulation factors and inhibitors. 
A patient with liver disease, whether acute or chronic, will often have an interfer-
ence of this ability to create clotting factors, which can range from mild to severe 
and life-threatening. While the etiology of the liver disease may vary from patient 
to patient, they will generally share the same hemostatic pattern. Often a patient 
with advanced liver disease will have significantly decreased levels of nearly all pro-
teins that promote or inhibit coagulation, fibrinolysis, and platelet function [10]. 
Adding to the challenge is not only that the traditional markers of coagulopathy, 
prothrombin time (PT) and activated partial thromboplastin time (APTT), cannot 
always accurately predict the risk of bleeding in these patients, but the traditional 
treatment of bleeding (blood transfusions) may not always help and can potentially 
be harmful in this subset of patients [10].
Hepatic surgery has become much more commonplace for a variety of reasons, 
but certainly improvements in surgical instruments and operative technique have 
played an important role. As previously discussed, a major driver of morbidity 
and mortality in liver surgery is blood loss and blood transfusions, and therefore 
any attempt to decrease postoperative bleeding is of interest to hepatic surgeons 
and researchers. Certain innovations such as maintaining low intraoperative CVP 
and creating total hepatic inflow occlusion have significantly improved outcomes 
for even aggressive hepatic resections [11]. Further advances to continue to reduce 
morbidity and mortality are constantly sought after.
Biosurgicals have been studied for use in hepatic surgery since their inception. 
Both non-active physical agents as well as biologically active agents have been tested 
and evaluated. Briefly, physical agents tend to promote hemostasis by stimulating 
platelets and the extrinsic pathway and by providing a scaffold for thrombus depo-
sition. A dry matrix can also act to absorb water, concentrate hemostatic factors at 
the site of bleeding, and exert a tamponade effect on the vessel by direct pressure. 
Biologically active agents on the other hand mimic endogenous coagulation, typi-
cally by directly introducing thrombin or fibrin topically to the site of bleeding.
When choosing a hemostatic agent during hepatobiliary surgery, the unique 
characteristics of the operative field and associated organs or structures needs to be 
taken into consideration. These characteristics will not only determine the type of 
hemostatic agent used (physical agent, biologically active agent, or combination), 
but also the delivery method (solid sheets, powder, liquid, etc.). Each unique situa-
tion may require a different solution, and the surgeon must be flexible.
As noted earlier, the hepatic parenchyma can pose a challenge for hemostatic 
control for multiple reasons. After a major liver resection, there may be a large 
surface area that is bleeding and requires attention. Additionally, the parenchyma 
may be irregular and have deep holes that are not easily accessible. Biologic agents 
such as fibrin sealants, which typically come in liquid form, can be preferred due to 
the ability to quickly deliver the agent over a large area so long as the bleeding is not 
brisk enough to dilute it too quickly [12]. However, using liquid agents accompanied 
by direct pressure may be problematic as they may be absorbed by a sponge or 
conversely if the sponge itself is damp with thrombin then this can provide for both 
coagulative and absorptive functions [12]. A solid physical agent such as collagen 
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matrix or oxidized cellulose may be preferred for use over a smaller or uniform area 
where direct pressure can be applied.
Besides fibrin, topical thrombin has also been used as an adjunct for hemostasis 
in hepatic resection, available as bovine thrombin, human plasma-derived throm-
bin, and recombinant human thrombin. It is one of the most used products avail-
able and has been accessible for decades; in fact bovine thrombin was in widespread 
use before it was even FDA approved 60 years ago [13]. However, bovine thrombin 
does carry the risk of antibody formation that can result in massive hemorrhage, 
anaphylaxis, and even death, as well as the risk of viral transmission [14]. The 
development of recombinant thrombin allowed for a product that had only minimal 
risk of antibody formation and also free from virus risk [14]. The other alternative is 
human thrombin, derived from human plasma donors, which carries similar risk of 
blood borne pathogens as blood products as it undergoes similar testing and filtra-
tion processes [14]. The ideal formulation of thrombin for hepatic surgery has yet to 
be discovered, but animal models of liver injury have shown superiority of smooth 
gelatin-thrombin hemostats in the ability to retain thrombin, and less intraoperative 
blood loss when compared to a stellate gelatin-thrombin hemostat [15].
Biosurgicals have primarily been investigated for two purposes in hepatobiliary 
surgery: maintenance of hemostasis and prevention of bile leak.
2.1 Preventing and maintaining hemostasis in hepatic surgery
Various agents for postoperative hemorrhage control have been studied and 
used in practice, but have mixed results in the literature. Animal models were 
first used to evaluate biosurgicals for hemostasis. In one case control study of liver 
injury in rat models, hot air coagulation, fibrin sealant, and suture hepatorrhaphy 
with horizontal mattress sutures were compared [16]. Data supported fibrin 
sealant to be the superior technique of the three considering it was very effective at 
achieving hemostasis and allowed the liver to return to its normal shape and more 
quickly regenerate [16]. There were some notable drawbacks however, including 
risk of abscess formation which was found to be higher than the hot air group 
but lower than suture technique. Other considerations included the high cost and 
prolonged preparation time, although both have improved significantly since this 
study was performed.
A series of important clinical studies of hemostatic agents in liver surgery have 
taken place over the past several decades. Fibrin sealants showed initial promise 
for providing hemostasis in the setting of major liver resection. The liquid form 
allows for sprayed fibrin sealant to be applied over a large cut surface area and 
easily gain access to any irregular groves or cuts within the parenchyma itself. While 
fibrin sealant has consistently demonstrated effectiveness in regards to time to 
hemostasis during surgery, or percentage of cases with complete hemostasis after a 
designated time, these results rarely have translated to improved clinical outcomes. 
Randomized controlled trials have unfortunately failed to show a reduction in clini-
cally important outcomes such as intraoperative blood loss, intra- or postoperative 
transfusion requirements, or bleeding episodes postoperatively [17–21]. Similarly 
disappointing results have been seen with a combination of bovine collagen and 
thrombin mixed then sprayed over the surgical bed [22]. Physical agents generally 
fare no better, as fibrin sealant has been shown to be roughly equivalent in terms of 
clinical outcomes when compared to either collagen powder or cellulose sheets in 
hepatic resections [23, 24].
Newer studies have evaluated a combination of collagen and coagulation 
factors, typically in the form of a so-called carrier-bound collagen sponge coated 
with fibrinogen and thrombin, commonly marketed as either Tachocomb or 
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Tachosil. Briceno et al. conducted a prospective, controlled, quasiexperimental 
study comparing the effectiveness of utilizing a ready-made coated collagen sponge 
(Tachosil) compared to no sponge in patients undergoing hepatectomy [25]. This 
study was probably the most favorable toward biosurgicals, as it demonstrated not 
only decreased transfusion requirements in the collagen sponge group, but also 
decreased mean hospital stay, moderate to severe postoperative complications, and 
drainage volume after collagen sponge use [25]. Notably these results were more 
prominent in the major hepatectomy subgroup, rather than those patients who 
underwent minor liver resections. Unfortunately while the aforementioned carrier-
bound collagen sponge appears to have abundant references in the literature, 
these impressive results have not been easily reproduced. Additional studies have 
failed to confirm significant improvement in intraoperative blood loss, intra- or 
postoperative transfusion requirements, clinically significant postoperative fluid 
collections, bleeding complications, or mortality when compared to control groups 
using argon beam coagulation or even other single agent biosurgicals such as plain 
oxidized regenerated cellulose [26–29]. Also interesting is that although nearly all 
studies demonstrate decreased time to hemostasis using these hemostatic agents, 
when explicitly measured the total operative time has actually been shown to be 
increased in this group [17]. Most recently Kobayashi et al. have tried to show 
further improvement with the use of a fibrin sealant and polyglycolic acid felt in a 
randomized controlled trial. When compared to a carrier-bound collagen sponge 
used during hepatic surgery, the fibrin sealant group had reduced overall morbid-
ity, infection, jaundice, and abdominal paracentesis rates, but of note was that the 
rates of hemorrhage were similar between the two groups [30]. Further studies are 
needed to confirm these early results for this novel agent combination.
Despite a lack of good quality and reproducible data demonstrating clinical 
effectiveness, biosurgicals are still widely used. This is likely due to anecdotal 
evidence, positive personal experience, or even word of mouth. Surgeons are using 
these agents not only to reduce bleeding during hepatic surgery, but for a host of 
other reasons. A Dutch national survey showed that topical agents were used by 
nearly 90% of surgeons during hepatic resection, with fibrin sealants being the 
most commonly used [31]. Surgeons reported using these agents to shorten time 
to hemostasis but also to reduce resection surface related complications such as 
postoperative hemorrhage, abscess formation, and bile leak [31]. A more recent sur-
vey of UK hepatobiliary specialists also revealed that a majority of surgeons (62%) 
admitted to using hemostatic adjuncts “routinely” during liver surgery while the 
remainder used them occasionally [32].
The best type of agent to assist hemostasis after hepatic resection is still not 
known. Increasing need for and performance of hepatic surgery will likely continue 
to drive use of any agents thought to reduce complications in these complicated and 
dangerous surgeries. At this time however, no specific agent can be recommend for 
routine use to reduce postoperative bleeding during hepatic surgery, and further 
studies still need to be conducted.
2.2 Preventing biliary leak/fistula
While thrombin products can be used to catalyze many reactions in the blood 
clotting cascade, the end product of arguably the most important reaction is a 
fibrin lattice or clot. Fibrin in the form of a sealant, often in conjunction with 
thrombin, is readily used in hepatobiliary surgery and not just for hemostatic 
purposes. Biosurgicals have also been evaluated for use in preventing a troublesome 
complication after hepatobiliary surgery – bile leak. However, proper evaluation of 
the literature on this subject is challenging because there has only recently been an 
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accepted consensus definition and grading of severity for bile leakage after hepato-
biliary surgery [33].
Initial studies in animal models examining the use of biosurgicals for prevention 
of biliary leak appeared promising. Biosurgical sealants were shown to be effective in 
reducing drain output and rate of bile leakage in pig models of purposely incomplete 
end-to-end choledochocholedochostomy [34]. However clinical trials on humans 
have not demonstrated similarly positive outcomes. Several recent systematic reviews 
and meta-analyses have failed to demonstrate significant reduction in biliary leakage 
rates with the use of fibrin sealants or other topical agents used intraoperatively com-
pared to standard treatments [35, 36]. The lack of conclusive results may at least be 
partially due to the heterogeneity among the current literature and failure of a stan-
dardized definition of bile leak until only recently. Further well-designed randomized 
controlled trials utilizing the current consensus definitions are necessary to clarify if 
any agents may be beneficial for preventing biliary leakage after liver resection.
3. Pancreatic surgery
The pancreas has long been an organ considered off limits to most surgeons 
in routine surgical situations. Its location deep within the abdomen, proximity to 
major vascular structures, and soft parenchyma have given it a reputation for being 
an unforgiving organ in surgery. As not only surgical technique but also anesthesia 
and critical care management have evolved over time, even extensive pancreatic 
resections are now undertaken on a regular basis. The need for pancreatic surger-
ies is expected to increase in the United States as the number of pancreatic cancers 
continues to rise [37]. These two factors in combination are expected to result in a 
dramatic rise in the number of pancreatic surgeries performed in the coming years.
The primary difficulties that the surgeon must overcome when operating on the 
pancreas include maintaining adequate hemostasis without simultaneously injuring 
the pancreatic parenchyma, pancreatic duct, and/or surrounding vascular structures 
and avoiding pancreatic leak and fistula formation. Pancreatitis may complicate any 
operation on the pancreas by obliterating the typical tissue planes around the pan-
creas, and the resultant inflammation may make the friable tissues bleed more easily. 
Additionally, in the setting of large pancreatic of duodenal tumors, the surgeon may 
be required to resect and reconstruct nearby veins or arteries in order to complete an 
appropriate oncologic resection with negative margins. Unfortunately, these chal-
lenges are often interrelated and may all occur in the same patient. Pancreatic cancer 
is known to be pro-inflammatory and is often associated with inflammation and 
pancreatitis changes. Large en bloc resections may require major vascular resections 
and can result in more severe intraoperative blood loss, while increased blood loss 
has been implicated in postoperative pancreatic fistula formation [38, 39].
Biosurgicals for use in pancreatic surgery have continued to gain in popularity, 
especially as more agents become readily available. Blood loss during pancreatic 
surgery is common and often voluminous. As an example, an amount of blood loss 
<400 ml during a pancreaticoduodenectomy falls into the lowest risk category for 
pancreatic fistula risk scoring systems, and blood loss in the 700–1000 ml range is 
common [39]. Blood loss in the setting of pancreatitis, both acute and chronic, can 
be even more severe as the inflamed tissues may bleed much more easily and major 
vascular structures cannot be as readily identified and preserved. Therefore, any 
strategies to reduce hemorrhage are welcomed by HPB surgeons.
While biosurgicals can be used to aid hemostasis just as in any other operation, 
significant interest has also been shown in the possibility that these agents could 
also help reduce the incidence or severity of pancreatic leaks and pancreatic fistulas 
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postoperatively. Despite advances in surgical technique and the availability of a 
multitude of advanced clips, staplers, and other adjuncts, the pancreatic fistula rate 
after pancreatic surgery remains high, with reports often 20% or more [38]. The very 
nature of many hemostatic agents as “glues” or “sealants” has led to investigating 
their effectiveness in prevention of pancreatic fistula formation. As long as pancreatic 
surgery remains technically challenging and fraught with potential complications, 
surgeons will be eager to adopt new methods and new agents. Biosurgicals offer sig-
nificant potential to aid the surgeon and patient toward better outcomes in pancreatic 
surgery.
3.1 Preventing and maintaining hemostasis in pancreatic surgery
The pancreas has a robust vascular supply and is in close proximity to several 
major named vascular structures, thus significant bleeding during pancreatic 
surgery can be common. This bleeding typically takes two forms: hemorrhage from 
the pancreatic parenchyma or bleeding from surrounding vascular structures such 
as portal vein, superior mesenteric vein, superior mesenteric artery, gastroduode-
nal artery, or any of their major branches. However, few studies have specifically 
evaluated the use of hemostatic agents in preventing or reducing bleeding during 
pancreatic surgery. Reports of the use of collagenic fleece to aid hemostasis in 
pancreatectomy and in the retroperitoneum after pancreatic resection have been 
reported with favorable results [40] but no rigorous prospective randomized con-
trolled trials have evaluated their hemostatic effects in this specific situation to date.
While biosurgical agents are generally effective at reducing blood loss and 
obtaining and maintaining hemostasis for major abdominal surgery, the efficacy is 
often related to the type of surgery. While there is a strong likelihood that hemo-
static agents are effective in assisting the surgeon to maintain hemostasis in pancre-
atic surgery, there is no data to support or refute those claims. Until specific studies 
are done in the setting of pancreatic surgery, we cannot specifically recommend 
any specific one biosurgical agent over another to reduce blood loss or transfusion 
requirements in these patients.
3.1.1 Graft bleeding (after venous resection/reconstruction)
As previously described, it has been established that excessive blood loss cor-
relates with higher risk of fistula formation among other postoperative complica-
tions [38, 39]. One of the sources of increased blood loss during pancreatic surgery, 
especially pancreatoduodenectomy, can be during venous reconstruction. Although 
initially controversial, vein resection is now the standard practice if the surgeon 
deems it necessary in order to achieve an R0 resection. This practice is currently 
recommended by most major surgical societies and are a part of the National 
Comprehensive Cancer Network (NCCN) guidelines [41, 42]. The ideal method 
of reconstruction is still not yet known but several options can be considered 
depending on the clinical situation and anatomy including primary end-to-end 
anastomosis, autologous interposition grafts (from internal jugular, saphenous, 
superficial femoral, gonadal, or external iliac veins), synthetic grafts (such as PTFE 
or bovine pericardium), or cadaveric allograft [43, 44]. As with any other vascular 
anastomosis, bleeding from suture lines can put the anastomosis at risk as well as 
prolong operative time. Thus, hemostatic agents can be effective here as well. Fibrin 
glues and other surgical sealants have shown significantly decreased bleeding time 
in vascular anastomoses compared to manual compression alone [45, 46]. Given 
this favorable data, it would be worthy of consideration to use these products for 
anastomoses with the goal of decreasing blood loss and operative time.
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3.2 Preventing pancreatic leak/fistula
As mentioned previously, biosurgicals have gained more widespread use in 
hepatobiliary surgery not just for their hemostatic properties alone. Postoperative 
pancreatic leaks and fistulas unfortunately remain common after pancreatic 
resection, and have the potential to significantly increase morbidity and even 
lead to mortality. Physical and biologic hemostatic agents are just the new wave of 
products that have peaked surgeons’ interest in preventing this morbid complica-
tion. Multiple attempts have been made to alter surgical technique, such as stapling, 
over-sewing the transection line, and main duct ligation to name a few. However no 
one technique has demonstrated reproducible and superior outcomes for reducing 
pancreatic fistula rates. Surgeons have now increasingly turned to adjunctive agents 
to assist in the avoidance of postoperative pancreatic fistula formation.
Evaluating interventions for pancreatic fistula formation are challenging for 
several reasons. Postoperative pancreatic fistulas can have a wide range of severity. 
While some pancreatic leaks remain asymptomatic and are only detected bio-
chemically, others cause severe clinical consequences requiring intervention and 
possibly resulting in sepsis and even death. Although pancreatic fistulas have been 
extensively studied and a large body of literature is dedicated to the subject, there 
has remained a lack of standardization of the definition of pancreatic fistula until 
only recently. In 2005 the International Study Group on Pancreatic Fistula (ISGPF) 
released a consensus definition and grading system of postoperative pancreatic 
fistula [47]. This was revised recently in 2017 and is now defined as “a drain output 
of any measurable volume of fluid with an amylase level >3 times the upper limit 
of institutional normal serum amylase activity, associated with a clinically relevant 
development/condition related directly to the postoperative pancreatic fistula” 
[48]. Prior to these guidelines being published, many studies suffered from non-
standard and differing definitions of pancreatic fistula and it was challenging to 
compare studies published from different institutions.
Fibrin sealants have been some of the first agents evaluated for pancreatic fistula 
prevention, first in the setting of distal pancreatectomy. In one of the earliest reported 
studies, Suzuki et al. demonstrated significantly decreased postoperative pancreatic 
fistula formation in a randomized controlled trial evaluating the use of fibrin glue on 
the suture line of the pancreatic stump during distal pancreatectomy for pancreatic 
and gastric cancer [49]. The pancreatic fistula rate was shown to decrease from 40% 
in the control group to 15.4% in the fibrin glue group. Several subsequent studies fur-
ther demonstrated that fibrin glue may be used to reduce the rate of pancreatic fistula 
formation [50, 51]. However, as discussed above, many studies were flawed from a 
lack of standard definition of pancreatic fistula, and results are difficult to extrapolate 
to modern times. Additional and more recent prospective trials evaluating fibrin glue 
in the setting of distal pancreatectomy have failed to support their ability to reduce 
pancreatic fistulas [52, 53]. Other attempts to inject fibrin glue directly into the main 
pancreatic duct in order to reduce fistula formation have similarly failed to show 
promise in improving outcomes [54]. A recent systematic review and meta-analysis as 
well as a recent Cochrane review have both concluded that based on the current avail-
able evidence, fibrin sealants likely have little to no effect on postoperative pancreatic 
fistula formation in patients undergoing distal pancreatectomy [55, 56].
Fibrin glue has also been evaluated as an adjunct to reinforce the pancreatic 
anastomosis after pancreaticoduodenectomy. Pancreatic fistulas in this setting, 
while slightly less common than after a distal pancreatectomy, can still cause 
significant morbidity. A major prospective randomized trial at Johns Hopkins 
sought to answer if fibrin glue may reduce postoperative pancreatic fistula forma-
tion after Whipple procedure [57]. While patients were only enrolled in the study 
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if the surgeon determined that the patient was at risk for pancreatic fistula (i.e. soft 
parenchyma and non-dilated pancreatic duct), one strength of this study was that 
surgical technique was controlled for and standardized. The treatment group had 
8 mL of fibrin glue applied to all three anastomoses while the control group had 
none. The rate of all pancreatic fistulas (both clinically relevant and silent) were 
26% in the treatment group and 30% in the control group; there was also no differ-
ence in overall complications, yielding the conclusion that application of fibrin glue 
provides no benefit [57]. While several retrospective or single arm observational 
studies have shown promise [58, 59], further prospective studies have failed to dem-
onstrate significant benefits to using fibrin glue during Whipple procedure [60, 61]. 
A Cochrane review on the subject could not conclude whether fibrin sealants were 
beneficial in the setting of pancreaticoduodenectomy, although the number and 
quality of studies are significantly less than those for distal pancreatectomy [55].
In addition to single agents such as fibrin, multi-agent compositions such as 
a carrier-bound collagen sponge coated with fibrinogen and thrombin have also 
received significant attention. These agents whether marketed as TachoComb or the 
newer product without added aprotinin and human (instead of bovine) thrombin 
known as TachoSil, but both appear to have similar efficacy [62]. A recent observa-
tional study comparing carrier-bound collagen sponge coated with fibrinogen and 
thrombin compared to both polyglycolic acid sheet only and a control group with no 
biologics did show a significantly decreased rate of clinically relevant (grade B or C) 
postoperative pancreatic fistula formation with the use of either of the two biosur-
gicals [63]. Unfortunately these results have not been further supported in rigorous 
prospective randomized controlled trials.
One of the first prospective studies to evaluate the effectiveness of these agents 
was a multicenter study in Italy evaluating patients undergoing distal pancre-
atectomy [64]. Patients were randomized to receive collagen sponge coated with 
fibrinogen and thrombin at the resection line or no reinforcement to the resection 
line. There was no standardization regarding surgical technique (surgeries were per-
formed laparoscopic or open, by stapling or suturing of the pancreatic margin, and 
with or without spleen preservation). While there was a reduction in drain amylase 
level on postoperative day #1 in the collagen sponge group, the rates of clinically 
relevant pancreatic fistulas were similar between the two groups as were length of 
days until drain removal and length of hospital stay [64]. A more recent multicenter 
prospective randomized French study had similar outcomes, where patients were 
randomized into either carrier-bound collagen sponge coated with fibrinogen and 
thrombin group or control group. While operative technique was not controlled, the 
technique for placing the sealant on the suture line was (overlap of 2.5 cm and direct 
pressure held for 3 min), and ISPGF definitions were used. Results of this trial 
demonstrated no statistically significant difference in the incidence of overall POPF 
(all grades) or in clinically relevant fistulas; the Tachosil group had an overall POPF 
rate of 54.5% and the control group a rate of 56.6% [65]. An additional multicenter 
randomized controlled Japanese study also failed to exhibit decreased fistula rates 
using a collagen sponge coated with fibrinogen and thrombin, demonstrating 
similar rates of overall POPF, including clinically relevant grade B and C fistulas 
[66]. The strengths of this study included uniform surgical technique (stapling of 
pancreas), rigorous criteria for the definition of pancreatic fistula according to the 
ISGPF guidelines, and a majority of surgeries were performed laparoscopically.
While promising and theoretically useful, at this time no conclusive evidence 
supports the use of biosurgicals for preventing pancreatic fistulas. The most robust 
data involve either fibrin glue or collagen sponge with fibrinogen and thrombin. 
The ideal agent or optimal method of application has not yet been discovered, and 
further studies are required to prove benefit at this time.
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4. Conclusions
In few other areas of surgery is the potential for and consequences of blood 
loss so great as in hepatobiliary and pancreatic surgery. It is clear to see why sub-
stantial time and resources have been put into finding adjuncts to obtaining and 
maintaining hemostasis in hepatic surgery. Not surprisingly, biosurgical agents 
have been used and evaluated during these procedures since their early introduc-
tion and adoption. While initial animal models often showed great promise in 
reducing intraoperative hemorrhage and postoperative bleeding complications, 
these benefits have generally not translated to real life clinical settings in humans. 
Intraoperative bleeding time and time to hemostasis are generally improved 
with the use of hemostatic agents in HPB surgery, but it is unclear what clinical 
benefits if any may be derived from those outcomes, considering total blood loss, 
transfusions requirements, and postoperative bleeding episodes remain generally 
unchanged. Similarly, rates of biliary and pancreatic leaks appear resistant to treat-
ment with biosurgical agents as well, as leak rates do not appear to differ when these 
agents are used. Despite these shortcomings, most surgeons admit to using biosur-
gicals regularly during HPB surgery, while sharing anecdotal episodes of clinical 
improvements. Great promise still remains.
We are still some time away from truly “bloodless” liver surgery. With the tradi-
tional clamps and sutures, clips and cautery we were able to begin safely operating 
on the liver and pancreas. Through novel energy devices and titanium staplers we 
have made great leaps and bounds to refine these surgeries to the point where they 
are now routinely offered to large numbers of patients worldwide. Biosurgicals 
provide an opportunity to take the next leap forward in hepatobiliary surgery, 
potentially even increasing the safety profiles of these major complex surgeries to 
little more than comparable outpatient procedures.
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